anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients were randomly assigned to two groups, On Day 1,each subject was to undergo laparoscopic cholecystectomy under general anesthesia. Anesthesia will be induced with fentanly (2-4ug/kg), propofol TCI (4ug/ml), rocuronium (0.6mg/kg), and maintaine with remifentanly(0.1-0.3ug/kg.h) , and propofol TCI (3-5ug/ml). At the end of the operation before wound closure, patients were randomized 1:1 to receive ropivacaine or placebo. In study group all wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery. All anesthetics will be stopped when wound infiltration completed. Patients will be send to PACU for monitor a while then back to ward. Record of pain intensity evaluation and rescue analgesic medication consumption were to continue through 48hours after administration of study drug. Pain intensity will be assessed by using a 0-10 point VAS scale. VAS-rest and VAS-coughing were recorded at the baseline ,2,4,6,8,12,18,24,48 hours. Postoperative Rescue analgesia consisit of Parecoxib Sodium 40mg be given by a nurse on requst of the subject to a maximum of 80mg per day.
FOSAMAX is not indicated for use in pediatric patients.

The safety and efficacy of FOSAMAX were examined in a randomized, double-blind, placebo-controlled two-year study of 139 pediatric patients, aged 4-18 years, with severe osteogenesis imperfecta (OI). One-hundred-and-nine patients were randomized to 5 mg FOSAMAX daily (weight less than 40 kg) or 10 mg FOSAMAX daily (weight greater than or equal to 40 kg) and 30 patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was -4.5. The mean change in lumbar spine BMD Z-score from baseline to Month 24 was 1.3 in the FOSAMAX-treated patients and 0.1 in the placebo-treated patients. Treatment with FOSAMAX did not reduce the risk of fracture. Sixteen percent of the FOSAMAX patients who sustained a radiologically-confirmed fracture by Month 12 of the study had delayed fracture healing (callus remodeling) or fracture non-union when assessed radiographically at Month 24 compared with 9% of the placebo-treated patients. In FOSAMAX-treated patients, bone histomorphometry data obtained at Month 24 demonstrated decreased bone turnover and delayed mineralization time; however, there were no mineralization defects. There were no statistically significant differences between the FOSAMAX and placebo groups in reduction of bone pain. The oral bioavailability in children was similar to that observed in adults.

The overall safety profile of FOSAMAX in osteogenesis imperfecta patients treated for up to 24 months was generally similar to that of adults with osteoporosis treated with FOSAMAX. However, there was an increased occurrence of vomiting in osteogenesis imperfecta patients treated with FOSAMAX compared to placebo. During the 24-month treatment period, vomiting was observed in 32 of 109 (29.4%) patients treated with FOSAMAX and 3 of 30 (10%) patients treated with placebo.

In a pharmacokinetic study, 6 of 24 pediatric osteogenesis imperfecta patients who received a single oral dose of FOSAMAX 35 or 70 mg developed fever, flu-like symptoms, and/or mild lymphocytopenia within 24 to 48 hours after administration. These events, lasting no more than 2 to 3 days and responding to acetaminophen, are consistent with an acute-phase response that has been reported in patients receiving bisphosphonates, including FOSAMAX. [See Adverse Reactions (6.2).]
PURPOSE:To obtain a novel carboxymethylcellulose (CMC) salt, by reacting a quaternary ammonium compound with a CMC having a specific carboxymethyl- substitution degree per glucose anhydride unit. CONSTITUTION:A quaternary ammonium salt of CMC of formula I [R is H or quaternary ammonium salt of carboxymethyl group; n is 10-1,000; the quaternary ammonium salt of the carboxymethyl group is the group of formula II (R<1>-R<4> are 1-30C aliphatic hydrocarbon group, aralkyl, etc.)] can be prepared in a separated and purified state, by mixing and reacting (A) a CMC having a carboxymethyl-substitution degree of 1.5-3.0 per glucose anhydride unit, or its salt with (B) the corresponding quaternary ammonium salt or its solution. EFFECT:A large amount of quaternary ammonium group can be introduced into CMC, and a salt soluble even in water and organic solvents can be prepared. USE:The product is used as a thickener, a dispersant, a protecting colloid, etc. in the form of a water-soluble polymer electrolyte.
Patients receive selinexor PO on days 1, 8 and 15, and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
The norelgestromin and ethinyl estradiol transdermal system uses a 28-day (four-week) cycle. A new patch is applied each week for three weeks (21 total days). Week Four is patch-free. Withdrawal bleeding is expected during this time.  


Every new patch should be applied on the same day of the week. This day is known as the “Patch Change Day.” For example, if the first patch is applied on a Monday, all subsequent patches should be applied on a Monday. Only one patch should be worn at a time. 

Do not cut, damage or alter the norelgestromin and ethinyl estradiol transdermal patch in any way. If the norelgestromin and ethinyl estradiol transdermal patch is cut, damaged or altered in size, contraceptive efficacy may be impaired. 

On the day after Week Four ends, a new four-week cycle is started by applying a new patch. Under no circumstances should there be more than a seven-day patch-free interval between dosing cycles.
The invention discloses a composition for treating a chicken enterovirus syndrome and its preparation method, and aims to provide a composition able to treat the chicken enterovirus syndrome, address both the symptoms and root causes, correct electrolyte balance and strengthen curative effects as well as a preparation method thereof. The composition comprises by weight: 15-25% of sulfaguanidine, 15-25% of, 3-7% of vitamin K, 5% of sodium chloride, 5% of potassium chloride, and the balance anhydrous glucose. The sulfaguanidine adopted in the invention is not adsorbed in chicken intestines. By contact killing of coccidians, dimetridazole can kill anacerobes causing the enterovirus syndrome. The combined use of sulfaguanidine and dimetridazole can be directed to kill coccidians and anacerobes causing the enterovirus syndrome. Potassium chloride and sodium chloride can correct electrolyte balance, and reduce adverse reactions caused by electrolyte loss due to chicken diarrhoea. Able to stop bleeding, vitamin K3 can reduce intestinal bleeding resulted from the enterovirus syndrome. Combined use of multiple drugs in the composition of the invention can effectively treat the enterovirus syndrome.
Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo one tablet PO daily for 3 years.
Disclosed is a method for extracting one or more chemical extracts from a plant product. The chemical extracts are purified and extracted by first separating at least a phytochemical bearing part of a plant product from one or more other portions of the plant product. A carrier oil is then heated at a target temperature to be used as the vehicle for extraction and then mixed with the at least a phytochemical bearing part while the target temperature is maintained. The process may be streamlined by having heating and mixing occur in a press device. The mixed carrier oil and the at least a phytochemical bearing part are then passed through the press device to produce an oil mixture. At least a chemical extract may be extracted from the oil mixture, and in some cases may be further purified by evaporation and/or centrifugation.
Systems and related methods providing for determining activities of individuals are discussed herein. Circuitry may be configured to wirelessly receive tag signals from a plurality of RF location tags. Two or more of the RF location tags may be positioned on an individual, such as at positions that may at least partially define a human frame. The circuitry may be configured to correlate the two or more RF location tags with the individual. Location data for each of the two or more RF location tags may be determined based on the received tag signals. An activity of the individual may be determined based on the location data. In some embodiments, one or more activities involving multiple individuals may be determined based on RF location tags and sensors positioned on each of the multiple individuals. Furthermore, sensor data from the sensors may be communicated over the UWB channel.
The disclosure provides a hybrid membrane camouflaged nanomedicine loaded with oxidative phosphorylation inhibitor and preparation method thereof. The nanomedicine comprises an inner core and an outer shell coated on the periphery of the inner core. The inner core is a ROS-responsive drug-loaded nanoparticle, and the drug loaded by the ROS-responsive nanocarrier is an oxidative phosphorylation inhibitor. The outer shell is a hybrid membrane of mitochondrial membrane and cancer cell membrane. The nanomedicines can cross the BBB and reach tumor sites by the homologous targeting of cancer cell membrane, and then they can homologously target and enter mitochondria by the mitochondrial membrane. Subsequently, under the high-level ROS environment of the mitochondria, the ROS responsive drug-loaded nanoparticle releases the oxidative phosphorylation inhibitor due to the swell and degradation of the inner core, so that the safe and efficient targeted GBM therapy is achieved.
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease that causes the walls of the lower heart chambers to thicken and stiffen. As the disease progresses, thickened walls around the left ventricle may block or reduce blood flow to the aorta, potentially interrupting the flow of oxygenated blood to the rest of the body. As a result, the heart must pump harder to overcome this obstruction and supply the body's circulation. HCM is initially suspected by the presence of an abnormal electrocardiogram (ECG) and confirmed by diagnostic imaging showing a left ventricular wall thickness of \>15mm (\>13mm in relatives of individuals with HCM or those who are genotype positive) that cannot be explained by another cardiac or general disease. The prevalence of HCM in the general population is 1:200 to 1:500 (\~750,000 Americans); however only 10-20% of cases are diagnosed, signifying an under-recognition of HCM in clinical practice and thus a need for better disease detection.

Viz HCM is a software device designed to alert and triage suspected HCM patients to the appropriate clinical care team. The device consists of an artificial intelligence algorithm embedded in a standalone mobile application. This is a prospective, open-label, multi-center workflow pilot. Viz HCM will be implemented at each participating site and all conforming incoming ECG recordings within a 6-month enrollment period will be analyzed using Viz HCM. The pilot will measure device utilization based on the percentage of HCM suspected notifications viewed by users. Among the number of viewed Viz suspected HCM cases, data will also be collected on time to follow-up as well as the type, date, and number of follow-up tests after notification. Impact of Viz HCM on clinical workflow will be established by comparing the number of HCM diagnosed patients (based on hospital records over the 6 months prior to site activation) \[pre-Viz\] to the number of HCM patients (flagged by Viz HCM and confirmed by follow-up transthoracic ECHO and/or CMR diagnostic imaging) after site activation \[post-Viz\]
PURPOSE:To produce the titled material effective to facilitate the manufacture of a denture base, by using a mixture of acrylic monomer and polymer as a raw material, adding a polymerization initiator and sensitizer reactive with visible light and ultraviolet ray to the material, and forming the obtained resin composition to a sheet having a specific thickness. CONSTITUTION:An acrylic monomer is added to powdery acrylic polymer, and the obtained raw material is mixed with a polymerization initiator and sensitizer reactive with visible light and ultraviolet ray to start the polymerization, e.g. benzyl, alpha-naphthyl, camphorquinone, etc. The obtained photosetting resin having sufficient plasticity to follow the surface shape of a jaw model and to keep the shape after releasing from the model is formed to a sheet of 0.5-5.0mm thick. Since the material is supplied in the form of a sheet, it can be cured rapidly by light irradiation after preparing the individual tray or basement having satisfactory shape. When a hole of 0.5-3.0mm diameter is bored to the sheet, it is especially advantageous in the use of a nonsticking impression material such as silicone, etc.
Graves' disease (GD) is the most frequent cause of hyperthyroidism, affecting mainly women aged 40-60 years. Radioiodine (¹³¹I), introduced in 1941, has become a cornerstone in the treatment of GD hyperthyroidism. Because of its safety, low costs and rapid effect, it is considered a first line therapy in the United States. However, treatment failure occurs in about 15-25% of patients treated with radioiodine. Patients not cured with the first dose of radioiodine usually present severe hyperthyroidism, characterized by large goiter, high 24-hour radioiodine uptake (24h-RAIU) and very high levels of thyroid hormones. We have previously shown that large goiter (≥48ml) is an independent predictor of treatment failure. In these patients, the therapeutic failure was 40.0% while in patients with smaller goiter was only 6.5% (P=0.005; unpublished). It is generally accepted that higher doses of radioiodine improves cure rates. Indeed, a recent meta-analysis found a correlation between radioiodine dose and therapeutic success in GD patients. To our knowledge, there are no published studies evaluating cure rates with different radioiodine doses in severe GD.
Anodal tDCS will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
OBJECTIVES: Cannabidiol (CBD), a component in Cannabis, is used to treat seizures, anxiety, and pain. Little is known about how effectively CBD works in managing chronic pain, a condition characterized by discomfort that persists beyond 3-6 months or beyond expected normal healing. Therefore, this systematic review aimed to synthesize evidence on the effectiveness of CBD in chronic pain management.
DESIGN: A systematic review of literature utilizing PRISMA 2020 guidelines.
DATA SOURCES: PubMed/MEDLINE, Web of Science, CINAHL, Academic Search Complete, PsycArticles, PsycINFO, SocINDEX, and CENTRAL. The gray literature search was performed through the World Health Organization, the Centers for Disease Control and Prevention, and the European Centre for Disease Prevention and Control.
REVIEW/ANALYSIS METHODS: We searched eight databases and gray literature for relevant studies until August 30, 2022. We gathered original research articles with various study designs published in English that looked at patients who used CBD to manage their chronic pain. Two authors assessed the risk of bias and certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach. We used narrative synthesis to analyze the results.
RESULTS: We included 15 studies among 1,516 identified articles. The majority of the studies indicated pain reduction ranging from 42% - 66% with CBD alone and CBD with Tetrahydrocannabinol. Three studies showed no significant improvement in reducing pain, and one had mixed findings in pain control. The included studies had various methods of measuring pain reduction, mostly through self-reporting and scales such as visual analog scales and verbal numerical scales, among others.
CONCLUSION: CBD may be useful in treating chronic pain. Findings should be interpreted with caution due to the small number of included studies and heterogeneity brought about by different study designs and outcome measures. More studies with robust study designs are warranted to evaluate CBD's effectiveness in treating chronic pain.
Alzheimer's disease (AD) is a complex multifactorial syndrome disease. In AD, two proteins play main role i,e, Aβ42 peptide and hyperphosphorylated microtubule associated protein (Tau) aggregation cause severe damages in both neuron cell membrane and key signal processing. There are other factors like loss of acetylcholine function, destabilization of microtubule also responsible for this disease. Therefore, the main challenge of the field is the multifactor property of this disease. Our main target is to develop a molecule which will target maximum factors of AD. Various attempts have been devoted towards this direction but clinical outcome is very less. Thus, the present invention provides a peptide of formula I, method of preparing the same and its pharmaceutical composition thereof.
PURPOSE: A systemic immunity or intestinal immunity adjuvant containing a Cheonggukjang extract as an active ingredient is provided to induce Th1 and Th2 responses against parenteral infectious pathogenic microorganisms, virus, cancer antigens, and general antigens as well as oral infectious pathogenic microorganisms during oral administration and to effectively produce a specific antibody. CONSTITUTION: A systemic immunity or intestinal immunity adjuvant contains a Cheonggukjang extract as an active ingredient. The Cheonggukjang extract contains an ethanol soluble ingredient which is prepared using ethanol. The ethanol is 50-99 % ethanol. The Cheonggukjang extract does not contain poly-gamma-glutamic acid (PGA) and levan. Cheonggukjang is prepared using Bacillus amyloliquefaciens. [Reference numerals] (AA,DD) Water extract; (BB) Bean; (CC,FF) 70%EtOH extract; (EE) Cheonggukjang
Experimental protocol:

28 women who are a healthy weight or overweight (aged 18-45 years) will be recruited to a randomized parallel trial to follow one of two 14-d hypo-energetic diets. Firstly, participants will consume a diet providing their estimated energy requirement (6 meals/day) for a 7 day standardisation period. After a one day laboratory visit, this will be followed by a 14 day intervention period when participants will follow a regular meal pattern (6 meals/d) or an irregular meal pattern (3-9 meals/d) (energy deficit of 800kcal/ 24h in both diets) (identical foods provided on both interventions whilst otherwise free living). Following a further laboratory visit day, they will then consume the previous standardisation diet providing their estimated energy requirement (6 meals/day) for a further 3 days. All foods to be consumed during the study will be provided to free of charge. These will comprise foods commonly consumed in the British diet and will be consumed in amounts designed to provide 800kcal/24h less than estimated energy requirements in the intervention period. Participants will attend the laboratory visits fasting and a blood sample will be obtained for fasting glucose, insulin and lipids. A test drink will then be given and over the following three hours measurements will be taken of energy expenditure (TEF). An ad libitum pasta test meal will be offered three hours after the test drink has been given. Subjective appetite ratings will be assessed while fasting, after the test drink, after the ad libitum meal, and during the intervention. Continuous interstitial glucose monitoring will be undertaken throughout the study. Ambulatory activity pattern measurement will be assessed in the intervention period. Core body temperature will be measured during the last 3 days of the first standardisation period, and during the final three standardisation days. Peripheral body temperature will be measured throughout the study period using a small i- button secured to the wrist. The study will commence at the early phase of the menstrual cycle (days1-7). A constant sleep-wake (and light exposure) routine will be followed for the whole study period which will be assessed by a written questionnaire form
Patients will receive inhaled normal saline, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat\>94% AND respiratory rate \<60 AND RDAI score \<4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
Cultural and generational trends have increasingly favored "anti-inflammatory" action, innovating a new class of analgesic, non-steroidal anti-inflammatory drugs (NSAIDs) in the 20th century. The modern human body has been molded over evolutionary time and while acknowledging inflammation can be pathologically entwined, it also serves an important role in healthy folliculogenesis and ovulation, shaping cues that drive needed vascular change. This review argues that because of anti-inflammatory action, the cultural invention of NSAIDs represents a particular stressor on female reproductive-age bodies, interacting with natural, underlying variation and placing limits on healthy growth and development in the follicles, creating potential autism risk through hypoxia and mutagenic or epigenetic effects. Since testes are analogs to ovaries, the biological grounding extends naturally to spermatogenesis. This review suggests the introduction of over-the-counter NSAIDs in the 1980s failed to recognize the unique functioning of reproductive-age bodies, challenging the cyclical inflammation needed for healthy gamete development. NSAIDs are framed as one (notable) stressor in an anti-inflammatory era focused on taming the risks of inflammation in modern human life.
PURPOSE: At our clinic, a significant portion of tonsillectomy (TE) preoperative assessments are conducted remotely. The aim of our study was to examine the variation in TE complications, contact rates, and reasons for patient contact between those evaluated preoperatively at the outpatient clinic (OPC), or remotely through virtual visits (VV), or via a digital care pathway (DCP). This investigation is critical for optimizing patient flow through the volume-intensive process of TE.
METHODS: We conducted a prospective cohort study involving 422 patients who underwent TE at Helsinki University Hospital ENT clinic to investigate their 30-day postoperative course. We extracted information on postoperative contacts, complications, and demographic data. Postoperative contact rate was the primary outcome measure to evaluate whether telehealth patients suffered fewer postoperative issues.
RESULTS: Patients from the OPC were least likely to seek medical assistance in the 30-day postoperative period. However, no significant difference was discovered compared to the remotely assessed DCP patients, and over entire TE episodes, the DCP patients had the fewest unplanned contacts compared to the VV and OPC cohorts. Furthermore, the care paths shared similar complication and contact method profiles with comparable post-tonsillectomy hemorrhage incidence.
CONCLUSION: A preoperative DCP for TE appeared to carry similar postoperative contact and complication rates, as well as comparable contact method profiles compared to the OPC model. Given the high patient satisfaction and cost-consciousness associated with the DCP, our findings encourage a broader implementation of highly developed DCPs in preoperative assessment for TE.
Participants will receive 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant will receive both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.